Gan & Lee Pharmaceuticals: Phase II Clinical Trial of GZR102 Injection Achieves Milestone with First Subject Dosing - 7x24

7 x 24 Track global technological trends

Hot Topic

Day

News Topic

Gan & Lee Pharmaceuticals: Phase II Clinical Trial of GZR102 Injection Achieves Milestone with First Subject Dosing

3 week ago / Read about 0 minute

Author：小编

Gan & Lee Pharmaceuticals' wholly-owned subsidiary has triumphantly concluded the first subject dosing in the Phase II clinical trial of its proprietary GZR102 injection in China. GZR102 represents a groundbreaking weekly formulation that combines basal insulin with GLP-1RA (Glucagon-Like Peptide-1 Receptor Agonist).

Previous page：Xin Guobin, Vice Minister of China's Ministry of I...

Next page：Raspberry Pi Launches High-Stakes Hacker Challenge...

Return to List

Hot Reading

2 day ago

2025 VW Jetta GLI: Save the manuals, but not like this

2 day ago

Corsair’s PC-dockable screen helped me monitor my PC components and news feeds

2 day ago

Huge Number of Authors Stand to Get Paid After Anthropic Agrees to Settle Potentially $1 Trillion Lawsuit

2 day ago

The AI Researchers That Mark Zuckerberg Lured to Work for Him With Huge Payments Are Already Quitting for Mysterious Reasons